COVID-19 vaccination in the United States

SnapNurse Launches SnapClinics to Provide Vaccinations in Areas of Need

Retrieved on: 
Tuesday, August 3, 2021
Technology, Nursing, Human resources, Professional services, Software, Health, Pharmaceutical, General Health, Data management, Biotechnology, Vaccination, Articles, Life sciences, Biology, COVID-19 vaccination in the United States, Vaccine hesitancy

SnapNurse , a disruptive, tech-enabled healthcare staffing platform, today announced the launch of SnapClinics, on-demand, pop-up vaccination clinics for healthcare deserts and underserved areas across the nation.

Key Points: 
  • SnapNurse , a disruptive, tech-enabled healthcare staffing platform, today announced the launch of SnapClinics, on-demand, pop-up vaccination clinics for healthcare deserts and underserved areas across the nation.
  • SnapClinics are designed to help public and private organizations with immunizations and other needs, with an immediate focus on providing COVID-19 vaccinations.
  • To date, SnapClinics in Arizona, California, Georgia, Florida and Michigan have vaccinated more than one million people across all vaccination sites.
  • We believe we can help educate people and provide access to COVID vaccines through our SnapClinics by meeting people where they are, said Cherie Kloss, SnapNurse founder and CEO.

Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations

Retrieved on: 
Thursday, June 10, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Medical research, BioNTech, Health sciences, COVID-19, Health, Pfizer–BioNTech COVID-19 vaccine, BioNTech, Pfizer, COVID-19 vaccine, COVID-19 vaccination in Italy, COVID-19 vaccination in the United States, Pfizer: Breakthroughs That Change Patients’ Lives, BioNTech, PFIZER: BREAKTHROUGHS THAT CHANGE PATIENTS’ LIVES, BIONTECH

The government will, in turn, donate the Pfizer-BioNTech vaccine doses to low- and lower middle-income countries and organizations that support them.

Key Points: 
  • The government will, in turn, donate the Pfizer-BioNTech vaccine doses to low- and lower middle-income countries and organizations that support them.
  • To date, Pfizer and BioNTech have shipped 700 million doses to more than 100 countries or territories around the world.
  • Based on current projections, Pfizer and BioNTech expect to manufacture up to 3 billion doses of the COVID-19 vaccine in 2021.
  • The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer.

Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations

Retrieved on: 
Thursday, June 10, 2021
Medical research, BioNTech, Health sciences, COVID-19, Health, Pfizer–BioNTech COVID-19 vaccine, BioNTech, Pfizer, COVID-19 vaccine, COVID-19 vaccination in Italy, COVID-19 vaccination in the United States

The government will, in turn, donate the Pfizer-BioNTech vaccine doses to low- and lower middle-income countries and organizations that support them.

Key Points: 
  • The government will, in turn, donate the Pfizer-BioNTech vaccine doses to low- and lower middle-income countries and organizations that support them.
  • To date, Pfizer and BioNTech have shipped 700 million doses to more than 100 countries or territories around the world.
  • Based on current projections, Pfizer and BioNTech expect to manufacture up to 3 billion doses of the COVID-19 vaccine in 2021.
  • The Pfizer-BioNTech COVID-19 vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer.

While Over Three-Quarters of Americans Are Willing to Take at Least One of the Authorized COVID-19 Vaccines, Nearly a Quarter Are Still Hesitant as the U.S. Changes Course on Mitigation Strategy

Retrieved on: 
Thursday, June 3, 2021
Medical specialties, Medicine, Health, Vaccination, Vaccine, Virology, Medical research, COVID-19 vaccines, Clinical trials, Science diplomacy and pandemics, COVID-19 vaccination in the United States

Furthermore, the number of Americans saying theyd be more likely to participate in a clinical trial doubled from 7% in 2020 to 13% in 2021.

Key Points: 
  • Furthermore, the number of Americans saying theyd be more likely to participate in a clinical trial doubled from 7% in 2020 to 13% in 2021.
  • This may show that Americans are far more versed on vaccine clinical trial data due to the U.S. government and vaccine makers communicating this information more effectively since fall 2020.
  • Transparency, consistency and accuracy in communication around the vaccines will be essential to turning the tide on the spread of the virus.
  • The figures have been weighted and are representative of all U.S. adults (aged 18+).

Houston Emergency Room Physician Urges Texans to get Vaccinated for COVID-19, Tells Women Under 50 to Choose Pfizer or Moderna Vaccines

Retrieved on: 
Thursday, May 20, 2021
Vaccination, Vaccine, Virology, Medical specialties, Health, COVID-19 vaccination in the United States

That is the question most Texans are currently grappling with as they decide whether to get vaccinated for COVID-19.\nHouston, TX emergency room physician, Dr. Michael Sarabia said there is an easy answer to that question: Get vaccinated as soon as you can .\nDr.

Key Points: 
  • That is the question most Texans are currently grappling with as they decide whether to get vaccinated for COVID-19.\nHouston, TX emergency room physician, Dr. Michael Sarabia said there is an easy answer to that question: Get vaccinated as soon as you can .\nDr.
  • Sarabia, a board-certified emergency medicine physician and Medical Director with SignatureCare Emergency Center in Atascocita/Humble, TX , said after attending to so many Texans with lung damage from COVID, his advice is for everyone to get vaccinated as soon as possible.\n"As an Emergency Medicine physician, I see patients every day who wish they had been vaccinated.
  • \'Get the first vaccine that is available to you.\' This has been the guidance up until most recently.
  • It now appears that women under the age of 50 should choose the Moderna or Pfizer vaccines if available, as opposed to the one produced by Johnson and Johnson," Dr. Sarabia said.\nSignatureCare Emergency Center owns and manages the fastest growing group of 24-hour emergency rooms throughout Texas.

Poll: Blacks Report BDO "Very Helpful" in Vaccine Decision

Retrieved on: 
Tuesday, May 4, 2021
Medicine, Health sciences, Vaccine hesitancy, Medical specialties, COVID-19 vaccine, Vaccine, COVID-19 vaccines, Clinical trials, COVID-19 vaccination in Bulgaria, COVID-19 vaccination in the United States

b'CHICAGO, May 4, 2021 /PRNewswire/ -- BlackDoctor.org (BDO) has been leading the charge in COVID-19 vaccine education since the beginning of the pandemic.

Key Points: 
  • b'CHICAGO, May 4, 2021 /PRNewswire/ -- BlackDoctor.org (BDO) has been leading the charge in COVID-19 vaccine education since the beginning of the pandemic.
  • That\'s over two-thirds of over 1600 respondents saying that BDO helped their decision to get vaccinated.
  • BDO polled their audience throughout the pandemic to gauge attitudes and concerns about the vaccines and identified a significant shift.
  • Vaccine hesitancy by Blacks was averaging around 60% but later dropped down to only 22% saying they will not get the vaccine.\nBDO recognized Blacks need information about when, where, and how to get the vaccine.

Walk-In COVID-19 Vaccinations Available at Alabama, North Carolina and Tennessee Publix Pharmacies

Retrieved on: 
Friday, April 30, 2021
Other Retail, Managed care, Other Consumer, Other Health, Health, Supermarket, General Health, Food, Beverage, Infectious diseases, Retail, Consumer, Medical specialties, Health, Publix, Vaccine, Johnson & Johnson COVID-19 vaccine, COVID-19 vaccination in the United States, COVID-19 vaccination in Bulgaria

b'Starting May 3, Publix Pharmacy locations in Alabama, North Carolina and Tennessee will accept walk-in customers who want to get the COVID\xe2\x80\x9119 vaccine, in addition to those who schedule appointments online.

Key Points: 
  • b'Starting May 3, Publix Pharmacy locations in Alabama, North Carolina and Tennessee will accept walk-in customers who want to get the COVID\xe2\x80\x9119 vaccine, in addition to those who schedule appointments online.
  • Vaccinations are provided to eligible individuals ages 18 and older, while supplies last.\nWalk-in customers may choose between the Moderna and Johnson & Johnson vaccines.
  • However, appointments are encouraged for the most efficient vaccination experience and to ensure the preferred vaccine is available.
  • The Johnson & Johnson vaccine requires only one dose.\nAppointments are required in Florida, Georgia, South Carolina and Virginia and are available in all seven states where we have stores.

Select Georgia and Tennessee Publix Pharmacies to Administer Johnson & Johnson COVID‑19 Vaccine

Retrieved on: 
Monday, March 22, 2021
Other Consumer, Health, Supermarket, Women, Seniors, Pharmaceutical, MEN, Infectious diseases, Retail, Family, Consumer, Publix, Medical research, Medicine, Health sciences, Health, Adenoviridae, COVID-19 vaccines, Clinical trials, COVID-19 vaccine, Vaccine, COVID-19 vaccination in the United States, Deployment of COVID-19 vaccines

Publix Pharmacy is expanding administration of the Johnson & Johnson COVID-19 vaccine into Georgia and Tennessee.

Key Points: 
  • Publix Pharmacy is expanding administration of the Johnson & Johnson COVID-19 vaccine into Georgia and Tennessee.
  • This is the first time the company is providing COVID-19 vaccinations in Tennessee and the first time providing the Johnson & Johnson vaccine in Georgia.
  • The vaccine will be available at 21 Georgia and 23 Tennessee Publix Pharmacy locations.
  • Publix pharmacies have also administered the COVID19 vaccine to eligible individuals in select Florida, South Carolina and Virginia locations.

Press release - COVID-19: latest on evaluation and authorisation of vaccines

Retrieved on: 
Monday, March 22, 2021
Medical research, COVID-19, Medicine, Health sciences, Adenoviridae, COVID-19 vaccines, Clinical trials, BioNTech, Societates Europaeae, COVID-19 vaccine, COVID-19 vaccination in Italy, COVID-19 vaccination in the United States

They will also discuss the EMAs recent evaluation of the AstraZeneca vaccine.

Key Points: 
  • They will also discuss the EMAs recent evaluation of the AstraZeneca vaccine.
  • When: Tuesday 23 March 2021, 10.00-11.00 (indicative timing)

    Where: European Parliament in Brussels, room Paul-Henri Spaak (3C050) and videoconference

    You can watch the debate live here.

  • Background

    Following positive scientific recommendations, the EMA has authorised four vaccines against COVID-19 for use in the EU (BioNTech-Pfizer, Moderna, AstraZeneca and Johnson & Johnson).

  • The EMA also started a rolling review of the Sputnik V vaccine (which is not part of the EUs COVID-19 vaccines portfolio).